Trial · NCT00445848
Adverse events111
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 111
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hemoglobin | Blood and lymphatic system disorders | Erlotinib and Bevacizumab | 19 | 85 | |
| other | Dry eye syndrome | Eye disorders | Erlotinib and Bevacizumab | 9 | 85 | |
| other | Ocular/Visual-Other | Eye disorders | Erlotinib and Bevacizumab | 6 | 85 | |
| other | Watery eye (epiphora, tearing) | Eye disorders | Erlotinib and Bevacizumab | 6 | 85 | |
| other | Constipation | Gastrointestinal disorders | Erlotinib and Bevacizumab | 13 | 85 | |
| other | Diarrhea | Gastrointestinal disorders | Erlotinib and Bevacizumab | 62 | 85 | |
| other | Dry mouth/salivary gland (xerostomia) | Gastrointestinal disorders | Erlotinib and Bevacizumab | 14 | 85 | |
| other | Flatulence | Gastrointestinal disorders | Erlotinib and Bevacizumab | 6 | 85 | |
| other | Heartburn/dyspepsia | Gastrointestinal disorders | Erlotinib and Bevacizumab | 13 | 85 | |
| other | Hemorrhage, GI - Oral cavity | Gastrointestinal disorders | Erlotinib and Bevacizumab | 7 | 85 | |
| other | Hemorrhage, GI - Rectum | Gastrointestinal disorders | Erlotinib and Bevacizumab | 8 | 85 | |
| other | Hemorrhoids | Gastrointestinal disorders | Erlotinib and Bevacizumab | 6 | 85 | |
| other | Mucositis/stomatitis (clinical exam) - Oral cavity | Gastrointestinal disorders | Erlotinib and Bevacizumab | 26 | 85 | |
| other | Mucositis/stomatitis (functional/symp) - Oral cav | Gastrointestinal disorders | Erlotinib and Bevacizumab | 18 | 85 | |
| other | Nausea | Gastrointestinal disorders | Erlotinib and Bevacizumab | 42 | 85 | |
| other | Pain - Abdomen NOS | Gastrointestinal disorders | Erlotinib and Bevacizumab | 19 | 85 | |
| other | Vomiting | Gastrointestinal disorders | Erlotinib and Bevacizumab | 20 | 85 | |
| other | Edema: limb | General disorders | Erlotinib and Bevacizumab | 14 | 85 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Erlotinib and Bevacizumab | 55 | 85 | |
| other | Fever in absence of neutropenia, ANC lt1.0x10e9/L | General disorders | Erlotinib and Bevacizumab | 7 | 85 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00445848/events